Get the Stockscreener App
3.875
3.12%
-0.125
Silexion Therapeutics Corp stock is traded at $3.875, with a volume of 104.64K.
It is down -3.12% in the last 24 hours and down -13.60% over the past month.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
See More
Previous Close:
$4.00
Open:
$4.02
24h Volume:
104.64K
Relative Volume:
0.22
Market Cap:
$2.84M
Revenue:
-
Net Income/Loss:
$-16.42M
P/E Ratio:
-0.1662
EPS:
-23.3189
Net Cash Flow:
$-6.75M
1W Performance:
-1.40%
1M Performance:
-13.60%
6M Performance:
-68.65%
1Y Performance:
-90.83%
1-Day Range:
$3.82
$4.07
1-Week Range:
$3.77
$4.20
52-Week Range:
$3.25
$63.45
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
3.875 | 12.51M | 0 | -16.42M | -6.75M | -23.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
What MACD and RSI say about Silexion Therapeutics CorpWeekly Trade Analysis & Capital Efficiency Focused Ideas - newser.com
Long term hold vs stop loss in Silexion Therapeutics CorpMarket Performance Summary & Weekly High Conviction Ideas - newser.com
Can Silexion Therapeutics Corp Equity Warrant stock beat analyst upgradesJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
Silexion Therapeutics Corp Equity Warrant stock outlook for YEAR2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
Silexion Therapeutics Corp stock trendline breakdownJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
What does recent volatility data suggest for Silexion Therapeutics Corp Equity WarrantWeekly Risk Report & Stock Market Timing Techniques - newser.com
What’s the recovery path for long term holders of Silexion Therapeutics Corp Equity WarrantJuly 2025 Macro Moves & Community Verified Swing Trade Signals - newser.com
Will Silexion Therapeutics Corp Equity Warrant stock go up soon2025 Market Overview & Consistent Income Trade Ideas - newser.com
How to integrate Silexion Therapeutics Corp Equity Warrant into portfolio analysis toolsMarket Risk Report & Reliable Price Breakout Signals - newser.com
Silexion Therapeutics Corp stock trend forecastJuly 2025 Drop Watch & High Return Trade Opportunity Guides - newser.com
Is it time to cut losses on Silexion Therapeutics CorpMarket Risk Summary & Entry Point Strategy Guides - newser.com
What Fibonacci levels say about Silexion Therapeutics Corp Equity Warrant reboundWeekly Trade Recap & Risk Controlled Swing Alerts - newser.com
Chart based analysis of Silexion Therapeutics Corp Equity Warrant trends2025 Top Decliners & Safe Capital Growth Tips - newser.com
What’s the recovery path for long term holders of Silexion Therapeutics Corp2025 Short Interest & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-10-09 04:43:28 - newser.com
Sentiment analysis tools applied to Silexion Therapeutics Corp Equity WarrantPortfolio Return Report & AI Powered Market Entry Ideas - newser.com
Live market analysis of Silexion Therapeutics Corp Equity WarrantPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Using Python tools to backtest Silexion Therapeutics Corp strategies2025 Earnings Impact & Risk Controlled Daily Trade Plans - newser.com
Silexion Therapeutics Corp Equity Warrant Stock Analysis and ForecastTechnical Pattern Recognition & Boost Wealth With Growth - earlytimes.in
How Silexion Therapeutics Corp Equity Warrant stock compares to market leadersMarket Growth Review & Free Fast Gain Swing Trade Alerts - newser.com
Multi asset correlation models including Silexion Therapeutics Corp Equity Warrant2025 Short Interest & Daily Technical Stock Forecast Reports - newser.com
Published on: 2025-10-05 07:04:01 - newser.com
What’s next for Silexion Therapeutics Corp stock price2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
What moving averages say about Silexion Therapeutics CorpOil Prices & Precise Buy Zone Identification - newser.com
Is this a good reentry point in Silexion Therapeutics CorpForecast Cut & Stock Market Timing Techniques - newser.com
Reversal indicators forming on Silexion Therapeutics Corp stockWeekly Investment Report & Weekly Stock Performance Updates - newser.com
Buy Rating Affirmed for Silexion Therapeutics: Promising Preclinical Data and Strategic Trial Plans Boost Investment Appeal - TipRanks
Silexion reports pan-KRAS inhibitor shows activity across cancer types By Investing.com - Investing.com Nigeria
Silexion Therapeutics Regains Compliance with Nasdaq - MSN
Silexion Therapeutics Unveils Promising SIL204 Data - TipRanks
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer - GlobeNewswire
Silexion reports pan-KRAS inhibitor shows activity across cancer types - Investing.com
Silexion Therapeutics climbs on promising cancer drug data - TradingView
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):